New prostate cancer treatment 2019

In 2019, several new prostate cancer treatments were approved or showed promising results in clinical trials. Here are some of the notable ones:

  1. Nubeqa (darolutamide): In June 2019, the FDA approved Nubeqa, a new oral medication for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). It is the first and only FDA-approved treatment for this specific type of prostate cancer.
  2. Erleada (apalutamide): In February 2019, the FDA approved Erleada, a new oral medication for the treatment of nmCRPC. It is the second FDA-approved treatment for this type of prostate cancer, and it is often used in combination with androgen deprivation therapy (ADT).
  3. Xtandi (enzalutamide): In November 2019, the FDA approved Xtandi, a new oral medication for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). It is the first FDA-approved treatment for this specific type of prostate cancer.
  4. Provenge (sipuleucel-T): In October 2019, the FDA approved Provenge, a new immunotherapy treatment for the treatment of asymptomatic or minimally symptomatic mCSPC. It is the first FDA-approved immunotherapy treatment for prostate cancer.
  5. Radioligand therapy: In 2019, several radioligand therapy (RLT) treatments were approved or showed promising results in clinical trials. RLT is a type of targeted radiation therapy that uses small molecules or antibodies to deliver radiation directly to cancer cells. Examples of RLT treatments include:
    • Lutetium Lu 177 vipivotide tetraxetan (Lu-177 vipivotide): Approved in June 2019 for the treatment of mCSPC.
    • Yttrium Y 90 ibritumomab tiuxetan (Zevalin): Approved in October 2019 for the treatment of mCSPC.
    • Actinium-225 alpha-particle immunotherapy: Showed promising results in a phase II clinical trial for the treatment of mCSPC.

These new treatments offer hope for patients with prostate cancer, particularly those with advanced or metastatic disease. However, it's essential to note that each patient's situation is unique, and the best treatment approach will depend on individual factors, such as the stage and grade of the cancer, overall health, and personal preferences.